The incretin-based medication landscape has evolved rapidly, moving from single-agonist drugs like semaglutide to dual-agonists like tirzepatide and now triple-agonists like retatrutide. Each generation targets additional receptor pathways, and the clinical trial data shows progressively greater weight loss outcomes. But more weight loss is not automatically better weight loss, and understanding the differences between these compounds matters for anyone making decisions about their health.
Mechanism Comparison
Semaglutide is a pure GLP-1 receptor agonist. It mimics the GLP-1 hormone, reducing appetite, slowing gastric emptying, and improving glucose metabolism through a single receptor pathway. This is the mechanism behind Ozempic (diabetes indication) and Wegovy (weight management indication).
Tirzepatide is a dual GLP-1/GIP receptor agonist. It activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. GIP has complex effects on metabolism, including enhanced insulin secretion and potential effects on fat tissue metabolism. The dual mechanism appears to produce greater weight loss and glucose improvements than GLP-1 alone.
Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist, the first compound to target all three pathways simultaneously. The addition of glucagon receptor activation increases energy expenditure and hepatic fat reduction, potentially offering advantages beyond what dual agonism achieves.
Clinical Trial Data
The pivotal trials for each compound show a clear progression in weight loss outcomes. Semaglutide 2.4mg (the STEP trials) produced average weight loss of approximately 15 to 17% of body weight over 68 weeks. Tirzepatide at its highest dose (the SURMOUNT trials) produced average weight loss of approximately 20 to 22% over 72 weeks. Retatrutide (phase 2 data) produced average weight loss of approximately 24% over 48 weeks at the highest dose, with the trajectory suggesting even greater loss with continued treatment.
These are population averages, and individual responses vary significantly. Some people respond more strongly to one mechanism than another, and genetic, metabolic, and behavioural factors all influence outcomes.
Side Effect Profiles
All three compounds share common gastrointestinal side effects: nausea, vomiting, diarrhea, and constipation. These are largely related to the GLP-1 component and typically improve over time with dose titration.
The key differentiator is that greater appetite suppression and faster weight loss create greater nutritional risk. When someone on retatrutide loses 24% of their body weight in under a year, the potential for lean mass loss, micronutrient deficiency, and metabolic adaptation is proportionally higher than with a slower trajectory.
Nutritional Implications
From a nutrition coaching perspective, the choice of medication influences the urgency and intensity of nutrition intervention. Higher-potency compounds require more aggressive protein targets to protect lean mass, more careful micronutrient monitoring, potentially more frequent body composition scanning, and greater attention to meal composition given reduced eating windows.
The fundamental nutrition principles remain the same regardless of which compound someone is taking: adequate protein, micronutrient density, appropriate caloric intake for the rate of loss, and resistance training. The implementation details change based on the degree of appetite suppression and the rate of weight loss.
What This Means for You
This article is educational, not prescriptive. The choice between these medications is a medical decision made between you and your prescriber based on your specific health profile, access, and treatment goals. We do not recommend one compound over another.
What we do recommend is that regardless of which medication you are taking, your nutrition strategy should match the intensity of the pharmacological intervention. The more potent the appetite suppression, the more deliberate your nutrition planning needs to be.
Frequently Asked Questions
Which GLP-1 medication is "best"? There is no universal best. Each compound has different mechanisms, side effect profiles, and access considerations. The best medication is the one your prescriber recommends for your specific situation. The best nutrition strategy is the one designed around your specific body composition data and goals.
Are these medications available in New Zealand? Semaglutide is available in New Zealand through prescription. Tirzepatide availability is evolving. Retatrutide is still in clinical development. Your GP or endocrinologist can advise on current access and funding status.
Will I need to adjust my nutrition plan if I switch medications? Yes. Switching compounds often changes appetite levels and side effect profiles, which requires nutrition adjustments. Regular body composition scanning helps identify when programme modifications are needed.
Whichever medication you are on, nutrition strategy matters. Explore our coaching packages designed to work alongside GLP-1 medications, and learn more about how these medications work.
